Brian D. Marsden

Oct 22, 2024 | nature.com | Maria Kiourlappou |Lisa Gartner |Nicholas E. Ilott |Fadi Issa |Joanna Hester |Jason Turner | +12 more

AbstractPrecision medicine in immune-mediated inflammatory diseases (IMIDs) requires a cellular understanding of treatment response. We describe a therapeutic atlas for Crohn’s disease (CD) and ulcerative colitis (UC) following adalimumab, an anti-tumour necrosis factor (anti-TNF) treatment. We generated ~1 million single-cell transcriptomes, organised into 109 cell states, from 216 gut biopsies (41 subjects), revealing disease-specific differences.

Jul 4, 2024 | nature.com | Aled Edwards |Ola Engkvist |David G. Hulcoop |Andrew Leach |Brian D. Marsden |Amelie Menge | +10 more

AbstractThe Structural Genomics Consortium is an international open science research organization with a focus on accelerating early-stage drug discovery, namely hit discovery and optimization. We, as many others, believe that artificial intelligence (AI) is poised to be a main accelerator in the field. The question is then how to best benefit from recent advances in AI and how to generate, format and disseminate data to enable future breakthroughs in AI-guided drug discovery.

Jun 24, 2024 | nature.com | Koen B. Pouwels |David Eyre |Thomas House |Nicole Stoesser |John Newton |Brian D. Marsden | +1 more

AbstractPopulation-representative estimates of SARS-CoV-2 infection prevalence and antibody levels in specific geographic areas at different time points are needed to optimise policy responses. However, even population-wide surveys are potentially impacted by biases arising from differences in participation rates across key groups.